Alkoxy compounds for disease treatment

Patent metadata

Field	Value
Publication number	US-10639286-B2
Application number	US-201816043019-A
Country	US
Kind code	B2
Filing date	Jul 23, 2018
Priority date	Oct 5, 2007
Publication date	May 5, 2020
Grant date	May 5, 2020

Abstract

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

First claim

What is claimed is:

1. A method of modulating chromophore flux in a retinoid cycle comprising introducing into a subject a non-retinoid aromatic compound that inhibits 11-cis-retinol production with an IC 50 of about 0.1 micromolar or less when assayed in vitro, the assay consisting of a homogenate of HEK293 cell clone expressing recombinant human RPE65 and LRAT as the source of visual enzyme, exogenous all-trans-retinol in the amount of about 20 μM, recombinant human CRALBP in the amount of about 80 μg/mL, about 10 mM pH 7.2 phosphate buffer, about 0.5% BSA and about 1 mM NaPPi, and wherein the amount of assay reaction product 11-cis-retinol being determined by HPLC analysis following heptane extraction of the assay reaction mixture and wherein the non-retinoid aromatic compound consists of a benzene core that is substituted with a first substituent, a second substituent, and an optional third substituent, wherein the first and second substituents are attached to the benzene core in a meta-substitution configuration, wherein the first substituent is an optionally substituted 3-aminoprop-1-yl group, the second substituent is a (c-C 6 H 11 )CH 2 —O— group, and the optional third substituent is a halogen or —OH; wherein the optionally substituted 3-aminoprop-1-yl group has the formula —C(R 9 )(R 10 )C(R 1 )(R 2 )CH 2 NH 2 ,
wherein R 1 and R 2 are each independently selected from hydrogen, halogen, C1-C5 unsubstituted alkyl, or —OR 6 ;
R 9 and R 19 are each independently selected from hydrogen, halogen, C1-C5 alkyl optionally substituted with hydroxy or halogen, or —OR 19 , and
R 6 , and R 19 are each independently hydrogen or CH 3 .

2. The method of claim 1 , wherein R 6 and R 19 are hydrogen.

3. The method of claim 1 , wherein R 9 is hydrogen.

4. The method of claim 2 , wherein R 9 is hydrogen.

5. The method of claim 1 , wherein R 10 is —OR 19 .

6. The method of claim 2 , wherein R 10 is —OR 19 .

7. The method of claim 3 , wherein R 10 is —OR 19 .

8. The method of claim 4 , wherein R 10 is —OR 19 .

9. The method of claim 1 , wherein R 10 is halogen.

10. The method of claim 2 , wherein R 10 is halogen.

11. The method of claim 3 , wherein R 10 is halogen.

12. The method of claim 4 , wherein R 10 is halogen.

13. The method of claim 1 , wherein R 1 is hydrogen.

14. The method of claim 4 , wherein R 1 is hydrogen.

15. The method of claim 8 , wherein R 1 is hydrogen.

Assignees

• Acucela Inc

Inventors

• Scott Ian L
• Kuksa Vladimir A
• Orme Mark W
• Little Jr Thomas L
• Gall Anna
• Hong Feng

Classifications

• C07C235/08

  having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms · CPC title

• C07C215/20

  the carbon skeleton being saturated and containing rings · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07C2601/02

  with a three-membered ring · CPC title

• C07C251/86

  having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings · CPC title